Literature DB >> 11289659

S-nitrosoglutathione inhibits TNF-alpha-induced NFkappaB activation in neutrophils.

J D Fortenberry1, M L Owens, N X Chen, L A Brown.   

Abstract

OBJECTIVE AND
DESIGN: Cytokine expression is controlled by transcription factors including NFkappaB, which has recently been found to exist in human neutrophils. We previously showed that exogenous nitric oxide (NO) induces neutrophil apoptosis and hypothesized that this NO effect could be mediated by inhibition of NFkappaB activation.
MATERIALS AND METHODS: Isolated human neutrophils were incubated with or without S-nitrosoglutathione (GSNO 0.1 mM-5 mM; Sigma) for 2 h. Neutrophils were either unstimulated or stimulated with TNFalphalpha or n-formyl methionyl leucine phenylalanine (fMLP). Viability was assessed by vital dye cytotoxicity assay. After nuclear extraction and measurement of protein concentration, NFkappaB binding was determined by electrophoretic mobility shift assay. Effects of GSNO on activation of IkappaB alpha, which inhibits intranuclear translocation of NFkappaB, were measured by Western immunoblot technique. For comparison, experiments were also performed in the presence of the NFkappaB inhibitor PDTC.
RESULTS: TNFalpha increased nuclear NFkappaB activity compared to unstimulated neutrophils (p < 0.001, n = 5). GSNO (500 microM) decreased TNFalpha-induced NFkappaB activity (p<0.05) and inhibited NFkappaB activity whether given prior to or during TNFalpha exposure. IkappaB alpha was significantly degraded at 30 and 120 min of TNFalpha exposure compared to control neutrophils (p < 0.05). GSNO exposure (500 microM) inhibited IkappaB alpha degradation in the presence of TNFalpha. PDTC enhanced neutrophil cell death and DNA fragmentation, in association with decreased NFkappaB activity, similar to GSNO effects.
CONCLUSION: Neutrophils possess NFkappaB activity that is increased by stimulation with TNFalpha. GSNO inhibits NFkappaB activity in association with inhibiting TNFalpha-induced degradation of IkappaB alpha. GSNO effects are similar to those seen with NFkappaB inhibition by PDTC. Inhibition of NF kappaB could represent a potential anti-inflammatory effect of GSNO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289659     DOI: 10.1007/s000110050729

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  13 in total

1.  S-Nitrosoglutathione administration ameliorates cauda equina compression injury in rats.

Authors:  Anandakumar Shunmugavel; Mushfiquddin Khan; Marcus M Martin; Anne G Copay; Brian R Subach; Thomas C Schuler; Inderjit Singh
Journal:  Neurosci Med       Date:  2012-09-25

2.  The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke.

Authors:  Mushfiquddin Khan; Tajinder S Dhammu; Harutoshi Sakakima; Anadakumar Shunmugavel; Anne G Gilg; Avtar K Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2012-11       Impact factor: 5.372

3.  Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.

Authors:  Xicheng Sun; Jan W F Wasley; Jian Qiu; Joan P Blonder; Adam M Stout; Louis S Green; Sarah A Strong; Dorothy B Colagiovanni; Jane P Richards; Sarah C Mutka; Lawrence Chun; Gary J Rosenthal
Journal:  ACS Med Chem Lett       Date:  2011-03-11       Impact factor: 4.345

4.  Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion.

Authors:  Harutoshi Sakakima; Mushfiquddin Khan; Tajinder S Dhammu; Anandakumar Shunmugavel; Yoshihiro Yoshida; Inderjit Singh; Avtar K Singh
Journal:  Restor Neurol Neurosci       Date:  2012       Impact factor: 2.406

5.  S-nitrosoglutathione a physiologic nitric oxide carrier attenuates experimental autoimmune encephalomyelitis.

Authors:  Narender Nath; Osamu Morinaga; Inderjit Singh
Journal:  J Neuroimmune Pharmacol       Date:  2010-01-21       Impact factor: 4.147

Review 6.  Nitric oxide in the pathogenesis of cardiac disease.

Authors:  Leopoldo Raij
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

7.  S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats.

Authors:  Mushfiquddin Khan; Harutoshi Sakakima; Tajinder S Dhammu; Anandakumar Shunmugavel; Yeong-Bin Im; Anne G Gilg; Avtar K Singh; Inderjit Singh
Journal:  J Neuroinflammation       Date:  2011-07-06       Impact factor: 8.322

8.  S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.

Authors:  Kolanjiappan Kaliyaperumal; Anand K Sharma; Daniel G McDonald; Jasdeep S Dhindsa; Caroline Yount; Avtar K Singh; Je-Seong Won; Inderjit Singh
Journal:  Redox Biol       Date:  2015-07-02       Impact factor: 11.799

9.  Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation.

Authors:  Joan P Blonder; Sarah C Mutka; Xicheng Sun; Jian Qiu; Lucia H Green; Navdeep K Mehra; Ramakrishna Boyanapalli; Michael Suniga; Kirsten Look; Chris Delany; Jane P Richards; Doug Looker; Charles Scoggin; Gary J Rosenthal
Journal:  BMC Pulm Med       Date:  2014-01-10       Impact factor: 3.317

10.  Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.

Authors:  Loretta G Que; Zhonghui Yang; Njira L Lugogo; Rohit K Katial; Steven A Shoemaker; Janice M Troha; David M Rodman; Robert M Tighe; Monica Kraft
Journal:  Immun Inflamm Dis       Date:  2018-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.